
Concizumab shows promise as a subcutaneous treatment option for hemophilia B with inhibitors, significantly reducing bleeding rates.


coremsg

The results are from the prospective, multicenter, phase 3 explorer7 trial, involving 133 patients, including 80 with hemophilia A and 53 had hemophilia B.

Hemophilia: Concizumab, a New Treatment Option?

concizumab-new-treatment-for-hemophilia-b-with-inhibitors


Concizumab: New Treatment for Hemophilia B with Inhibitors
